BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 33302035)

  • 1. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.
    Bolarin JA; Oluwatoyosi MA; Orege JI; Ayeni EA; Ibrahim YA; Adeyemi SB; Tiamiyu BB; Gbadegesin LA; Akinyemi TO; Odoh CK; Umeobi HI; Adeoye AB
    Int Immunopharmacol; 2021 Jan; 90():107228. PubMed ID: 33302035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
    Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
    Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs repurposing for SARS-CoV-2: new insight of COVID-19 druggability.
    Debnath SK; Debnath M; Srivastava R; Omri A
    Expert Rev Anti Infect Ther; 2022 Sep; 20(9):1187-1204. PubMed ID: 35615888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled therapy for COVID-19: Considerations of drugs, formulations and devices.
    Saha T; Quiñones-Mateu ME; Das SC
    Int J Pharm; 2022 Aug; 624():122042. PubMed ID: 35868481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection.
    Khare P; Sahu U; Pandey SC; Samant M
    Virus Res; 2020 Dec; 290():198169. PubMed ID: 32979476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapies under investigation for COVID-19: potential COVID-19 treatments.
    Weisberg E; Sattler M; Yang PL; Parent A; Gray N; Griffin JD
    Can J Physiol Pharmacol; 2020 Aug; 98(8):483-489. PubMed ID: 32640179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral therapy for coronavirus disease 2019.
    Gong S; Su J; Yan X; Li F; Hu L; Liu S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19.
    Ünlü B; Simsek R; Köse SBE; Yirün A; Erkekoglu P
    Mini Rev Med Chem; 2022; 22(2):213-231. PubMed ID: 34191697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
    Dinda B; Dinda M; Dinda S; De UC
    Eur J Med Chem; 2023 Oct; 258():115629. PubMed ID: 37437351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
    Abd El-Aziz TM; Stockand JD
    Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of repurposed antiviral drugs: Lessons from COVID-19.
    Martinez MA
    Drug Discov Today; 2022 Jul; 27(7):1954-1960. PubMed ID: 35192924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.